Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes).

Next Previous
Trial Profile

RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TSUBAKI study
  • Sponsors Kyowa Hakko Kirin; Kyowa Kirin

    • Most Recent Events

    • 11 Oct 2019 According to a Reata Pharmaceuticals media release, safety data from four studies ( NCT03019185, NCT03366337, NCT02316821 and NCT02036970 will be presented at at the American Society of Nephrology Kidney Week 2019 Annual Meeting. Abstract are available on the conference website at https://www.asn-online.org/education/kidneyweek/archives/.
    • 04 Jun 2018 According to a Reata Pharmaceuticals media release, based on the data of this study and other data, Kyowa Hakko Kirin received SAKIGAKE Designation for bardoxolone for the treatment of diabetic kidney disease by the Japanese Ministry of Health, Labour and Welfare in March 2018.
    • 06 Nov 2017 According to a Reata Pharmaceuticals media release, results from this trial were presented at the 2017 American Society of Nephrology Kidney Week meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top